Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16996136 | 0.96 | ESR1 (0.42) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL16996429 | 0.95 | ESR1 (0.41) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL24750111 | 0.94 | ESR1 (0.40) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL17804680 | 0.94 | ESR1 (0.43) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL19494819 | 0.92 | ESR1 (0.37) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL16996100 | 0.90 | ESR1 (0.38) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL17854346 | 0.89 | MEN1 (0.47) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL17854341 | 0.89 | MEN1 (0.47) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL17854588 | 0.88 | MEN1 (0.46) | ESR1ESR2KDM4EMEN1LMNA | |
| SCHEMBL15290091 | 0.88 | ESR1 (0.40) | ESR1ESR2KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10944057-B2 | Compound, material for organic electroluminescence devices, organic electroluminescence device, and electronic equipment | IDEMITSU KOSAN CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20180130968-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180130968-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20160176801-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICES, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176801-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICES, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10944057-B2 | Compound, material for organic electroluminescence devices, organic electroluminescence device, and electronic equipment | OR10J3, KCNA5, KCNK10 | ESR1 54/4885ESR2 155/4885KDM4E 783/4885 |
| US-20180130968-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE | RER1, NR0B1, NR2E1 | ESR1 152/4885ESR2 37/4885KDM4E 4144/4885 |
| US-20160176801-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICES, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT | OR10J3, KCNA5, KCNK10 | ESR1 54/4885ESR2 155/4885KDM4E 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.